Management of stage III non–small-cell lung cancer: ASCO guideline

ME Daly, N Singh, N Ismaila, MB Antonoff… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE To provide evidence-based recommendations to practicing clinicians on
management of patients with stage III non–small-cell lung cancer (NSCLC). METHODS An …

Radiation oncology in the era of precision medicine

M Baumann, M Krause, J Overgaard, J Debus… - Nature Reviews …, 2016 - nature.com
Technological advances and clinical research over the past few decades have given
radiation oncologists the capability to personalize treatments for accurate delivery of …

Lung cancer: Biology and treatment options

H Lemjabbar-Alaoui, OUI Hassan, YW Yang… - … et Biophysica Acta (BBA …, 2015 - Elsevier
Lung cancer remains the leading cause of cancer mortality in men and women in the US
and worldwide. About 90% of lung cancer cases are caused by smoking and the use of …

Management of non-small-cell lung cancer: recent developments

M Reck, DF Heigener, T Mok, JC Soria, KF Rabe - The Lancet, 2013 - thelancet.com
Non-small-cell lung cancer is one of the leading causes of deaths from cancer worldwide.
Therefore, improvements in diagnostics and treatments are urgently needed. In this review …

Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non–small-cell lung cancer

A Aupérin, C Le Péchoux, E Rolland… - Journal of clinical …, 2010 - ascopubs.org
Purpose The previous individual patient data meta-analyses of chemotherapy in locally
advanced non–small-cell lung cancer (NSCLC) showed that adding sequential or …

Non-small-cell lung cancer

P Goldstraw, D Ball, JR Jett, T Le Chevalier, E Lim… - The Lancet, 2011 - thelancet.com
In the decade since the last Lancet Seminar on lung cancer there have been advances in
many aspects of the classification, diagnosis, and treatment of non-small-cell lung cancer …

Treatment of stage III non-small cell lung cancer: Diagnosis and management of lung cancer: American College of Chest Physicians evidence-based clinical practice …

N Ramnath, TJ Dilling, LJ Harris, AW Kim, GC Michaud… - Chest, 2013 - Elsevier
Objectives Stage III non-small cell lung cancer (NSCLC) describes a heterogeneous
population with disease presentation ranging from apparently resectable tumors with occult …

Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms

G Goeckenjan, H Sitter, M Thomas, D Branscheid… - …, 2010 - thieme-connect.com
Qualitätsindikatoren wurden durch Sens et al. wie folgt definiert:„Ein Indikator ist ein
quantitatives Maß, welches zum Monitoring und zur Bewertung der Qualität wichtiger …

[HTML][HTML] Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

L Crino, W Weder, J Van Meerbeeck, E Felip… - Annals of oncology, 2010 - Elsevier
Improving survival in lung cancer is a major challenge for modern oncology considering that
5-year survival remains< 15%, across all stages of disease and with< 7% of patients alive 10 …

Multinational randomized phase III trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage …

JS Ahn, YC Ahn, JH Kim, CG Lee, EK Cho… - Journal of Clinical …, 2015 - ascopubs.org
Purpose To determine the efficacy of consolidation chemotherapy (CC) with docetaxel and
cisplatin (DP) after concurrent chemoradiotherapy (CCRT) with the same agents in locally …